Furthermore, last month, Roche’s IL-6 inhibitor Actemra/RoActemra (tocilizumab) also failed to show a benefit in an Italian study involving patients with early-stage COVID-19 pneumonia.

Disclosure: Dr. Sebba has received financial support in the form of research grants and lecture honoraria from Hoffmann-La Roche Inc. Cells producing interleukin-6 (IL-6) and the actions of IL-6 ...

Bristol–Myers Squibb (BMS) has entered a potential ∼US$1 billion agreement with Alder Biopharmaceuticals involving Alder's lead drug ALD518, a humanized monoclonal antibody specific for ...

"Similar trends" that fell short of statistical significance were also seen when JAK inhibitors were compared with less ...

Learn what to expect... By Erica Patino March 18, 2024 What to Expect When You’re Starting an IL-6 Inhibitor to Treat Rheumatoid Arthritis What to Expect When You’re Starting an IL-6 ...

Celltrion's biosimilar Avtozma, used to treat inflammatory diseases, was approved for the U.S. market by the Food and Drug Administration.

Inhibiting the entire receptor complex prevents IL-6 signal transduction to inflammatory ... sufficiently to methotrexate. Since IL-6R inhibition has a distinct mechanism of action, some patients ...